micro-community-banner
Profile Image
  • Add Media
  • Saved

2yr
Tackling obesity and weight loss

The prevalence of obesity is expected to reach 49% by 2023, and this chronic, relapsing disease is linked to comorbidities, including T2DM, dyslipidemia, hypertension, CAD, stroke, and certain cancers. The total financial costs of chronic conditions linked to obesity are estimated at $1.71 trillion. The effective weight management of patients with obesity is necessary to optimize quality of life, minimize medical and financial costs, and decrease morbidity and mortality.

Various weight-loss interventions have been developed, including diet/exercise lifestyle interventions; antiobesity medications (AOMs); surgical interventions, and endoscopic interventions. AOMs are effective and improve quality of life and decrease the risk of weight-related comorbidities. Nevertheless, AOMs demonstrate a wide variation in the percentage of weight loss, between 5% and 12%, per the results of clinical trials.

Five FDA-approved AOMs are semaglutide, liraglutide, orlistat, phentermine plus topiramate, and naltrexone plus bupropion. These drugs are indicated for long-term use in patients with a BMI ≥ 30 without weight-related comorbidities and a BMI ≥ 27 in those with weight-related comorbidities.

Are you discussing anti-obesity medications with your patients more proactively? Please share your current comfort in prescribing anti-obesity medications.

Profile Image

Show More Comments

  • Saved

2yr

Editorial: Incretin agonists in the treatment of obesity

Source : https://www.frontiersin.org/articles/10.3389/fendo.2023.1265826/full

Obesity has emerged as a critical global public health concern over the past decade.Studies have demonstrated that even a modest weight reduction significantly decreases the risk of developing obesity-related complications...

Conclusions: Overall, the escalating prevalence of obesity presents a pressing global health challenge. The articles presented with the Research Topic highlight the crucial role of various incretin agonists in weight reduction and improvement of cardiometabolic profiles. Nevertheless, ongoing research is vital to refine and expand the arsenal...

Profile Image
  • Saved

2yr
Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis - Cardiovascular Diabetology

Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis - Cardiovascular Diabetology

Source : https://cardiab.biomedcentral.com/articles/10.1186/s12933-023-01949-7

Background Semaglutide is a glucose-lowering treatment for type 2 diabetes (T2D) with demonstrated cardiovascular benefits; semaglutide may also have kidney-protective effects. This post hoc analysis investigated the association between major...

Conclusions: MACE risk was greater for participants with kidney impairment or damage than for those without. Semaglutide consistently reduced MACE risk across eGFR and UACR subgroups, indicating that semaglutide provides cardiovascular benefits in people with T2D and at high cardiovascular risk across a broad spectrum of kidney function and...

Profile Image
  • Saved

2yr
The role of weight control in the management of type 2 diabetes mellitus: Perspectives on semaglutide - PubMed

The role of weight control in the management of type 2 diabetes mellitus: Perspectives on semaglutide - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37591343/

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used to address multiple aspects of type 2 diabetes mellitus (T2DM) management, including glycaemic control, weight loss, and cardiovascular risk reduction. Semaglutide,...

Conclusions/Relevance: Thus, semaglutide offers a well-established therapeutic option that aligns well with guideline recommendations for T2DM management, emphasizing the high importance of weight control and amelioration of other cardiometabolic risk factors.

Profile Image
  • Saved

2yr
Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus - PubMed

Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37541792/

The LiRa_NL group showed the most weight loss, although the discontinuation rate was high. Most side-effects occurred at 1-2 months. When prescribing GLP-1 RA, education concerning side-effects and discontinuation is...

Conclusions: The LiRa_NL group showed the most weight loss, although the discontinuation rate was high. Most side-effects occurred at 1–2 months. When prescribing GLP-1 RA, education concerning side-effects and discontinuation is needed to enhance treatment adherence.

Profile Image